Sun Pharma has resolved its U.S. patent litigation with Incyte Corporation, securing a license to launch LEQSELVI (deuruxolitinib) for severe alopecia areata. This strategic move enables Sun to enter the U.S. dermatology market with a high-impact JAK inhibitor, offering new hope to millions affected by the autoimmune disorder.
On July 9, 2025, Indian markets faced global headwinds as US tariff hikes targeted pharma and metals, but strong domestic developments in steel, infra, and upcoming IPOs like Anthem Biosciences kept investor sentiment balanced.
Indian stock markets ended strong on July 8, 2025, backed by institutional buying, upbeat earnings from key companies like Kotak Bank and M&M, and positive momentum in realty and banking sectors, even as global tariff tensions weighed on sentiment.
Nectar Lifesciences sells its core API, formulation & menthol businesses to Ceph Lifesciences for ₹1,290 Cr. Learn about the deal structure, strategy, and market impact.
Despite global trade friction and sectoral rotation in equities, India Inc continues to post encouraging earnings in healthcare, retail, and banking—setting the tone for a resilient FY26.